Traditional antibody discovery often prioritises binding before function, adding complexity to screening and potentially overlooking valuable candidates. This whitepaper explores how bringing functional assessment earlier into the discovery workflow could help researchers identify relevant antibody leads sooner and make more informed decisions about which candidates to progress.

Readers will learn:

• Why binding-first workflows can miss functionally valuable antibody candidates
• How single-cell functional screening can support earlier, more informed lead selection
• How integrating functional assays and viable cell recovery could streamline antibody discover

 

Brought to you by